The choice you make today can help fuel the cures of tomorrow. Donate now

Close Icon

Maksim Mamonkin, Ph.D.

Maksim Mamonkin, Ph.D., is an associate professor in the Department of Pathology & Immunology and the Center for Cell and Gene Therapy at Baylor College of Medicine.  Dr. Mamonkin also is a scientific co-founder and the chief scientific officer of March Biosciences, a clinical-stage biotech company developing engineered T-cells for challenging indications. 

He is a translational immunologist engineering cellular therapies for hematologic malignancies and alloimmunity. His group has developed fratricide-resistant CD5 CAR T-cells targeting T-cell lymphoma and leukemia. Further, they utilized genome editing tools and pharmacologic inhibitors to create CD7-edited and unedited CD7 CAR T-cells for the therapy of T-cell lymphoblastic malignancies and AML. They uncovered mechanisms by which tonic CAR signaling produces toxicity in T-cells and described solutions to minimize these unwanted effects in therapeutic T-cells. His team has translated these findings to the clinic and developed optimized cGMP manufacturing protocols for CAR-T cells in ongoing first-in-man phase I clinical trials in patients with T-cell malignancies and AML in this we coordinate GMP manufacturing, release, and correlative studies.

More recently, he extended his interest in targeting T-lineage antigens to develop engineered receptors that suppress T-cell-driven alloimmunity, including host rejection of allogeneic cell therapies and graft-versus-host disease. They utilized these tools to create non-alloreactive, off-the-shelf CAR T-cell therapies resistant to host immune rejection and effective against graft-versus-host disease, technologies that have been licensed to leading cell therapy companies.

About March Biosciences

The Science: The phase I study of CD5.CAR-T at Baylor’s Center for Cell and Gene Therapy has shown compelling signs of efficacy and safety. 

  • 60% (6/10) complete responses across T-cell leukemia and lymphoma, when standard of care is only 10 to 20% complete responses 
  • March Biosciences is moving MB-105 (CD5.CAR-T) to Phase II trials for T-cell lymphoma this year 

Pipeline: March Biosciences is expanding into T-cell targeting for autoimmune diseases, a completely novel strategy to drive curative responses in these chronic conditions. 

Funding: March Biosciences had $22.5 million in funding committed or actualized in 2023, including: 

  • A $13.4 million grant from the Cancer Prevention and Research Institute of Texas to support the phase II trial. 
  • A $4.8 million investment from the Cancer Focus Fund to support the phase II trial. 

Series A: March Biosciences is syndicating a $20 million Series A round, with a potential lead identified.  

Next Steps: March Biosciences will focus efforts on initiating the phase II trial. 

To join us for An Evening of Partnership and Discovery, please RSVP below.